Pharmacist‐led, technology‐assisted study to improve medication safety, cardiovascular risk factor control, and racial disparities in kidney transplant recipients
Authors:
- 21 June 2018
- journal article
- research article
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 1 (2) , 81-88
Abstract
Background: Health disparities in African‐American (AA) kidney transplant recipients compared with non‐AA recipients are well established. Cardiovascular disease (CVD) risk control is a significant mediator of this disparity.Objective: To assess the efficacy of improved medication safety, CVD risk control, and racial disparities in kidney transplant recipients.Methods: Prospective, pharmacist‐led, technology‐aided, 6‐month interventional clinical trial. A total of 60 kidney recipients with diabetes and hypertension were enrolled. Patients had to be at least one‐year posttransplant with stable graft function. Primary outcome measured included hypertension, diabetes, and lipid control using intent‐to‐treat analyses, with differences assessed between AA and non‐AA recipients.Results: The participants mean age was 59 years, with 42% being female and 68% being AA. Overall, patients demonstrated improvements in blood pressure P = 0.054) and hemoglobin A1c (HgbA1c) P = 0.061). African‐Americans demonstrated a significant reduction from baseline in systolic blood pressure (−0.86 mmHg per month, P = 0.026), which was not evident in non‐AAs (−0.13 mmHg per month, P = 0.865). Mean HgbA1c decreased from baseline in the overall group (−0.12% per month, P = 0.003), which was similar within AAs (−0.11% per month, P = 0.004) and non‐AAs (−0.14% per month, P = 0.029). There were no changes in low‐density lipoproteins, triglycerides, or high‐density lipoproteins over the course of the study. Medication errors were significantly reduced and self‐reported medication adherence significantly improved over the course of the study.Conclusion: These results demonstrate the potential efficacy of a pharmacist‐led, technology‐aided, educational intervention in improving medication safety, diabetes, and hypertension and reducing racial disparities in AA kidney transplant recipients (ClinicalTrials.gov NCT02763943).Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (K23DK099440)
This publication has 44 references indexed in Scilit:
- Management of High Blood Pressure in African Americans and the 2010 ISHIB Consensus Statement: Meeting an Unmet NeedThe Journal of Clinical Hypertension, 2010
- African American Kidney Transplantation SurvivalDrugs, 2009
- Sirolimus improves the two-year outcome of renal allografts in African-American patientsTransplant International, 2001
- Sirolimus improves the two-year outcome of renal allografts in African-American patientsTransplant International, 2001
- Kidney transplantation: Racial or socioeconomic disparities?American Journal of Kidney Diseases, 1999
- RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1Transplantation, 1998
- Why are African Americans under‐represented in medical research studies? Impediments to participationEthnicity & Health, 1997
- Racial differences in renal allograft survival: The role of systemic hypertensionKidney International, 1995
- Racial Differences in the Survival of Cadaveric Renal AllograftsNew England Journal of Medicine, 1992
- NONCOMPLIANCE IN ORGAN TRANSPLANT RECIPIENTSTransplantation, 1990